TrialThe lancet. Diabetes & endocrinology2017

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

Bo Ahrén et al.PubMed ↗Publisher ↗

No numbers read from the abstract.